Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $24.67 Analyst target: $36.20 Upside: 46.74%
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. The company is headquartered in Boulder, Colorado.
See the full interactive analysis & chart →Informational only — not investment advice.